Drugs / MEDI3617
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02141542 | May 2014 → Sep 2020 | metastatic melanoma | F. Stephen Hodi, MD | Completed | No outcome recorded |
| Phase 1 | NCT01248949 | Oct 2010 → Jul 2015 | ovarian cancer | MedImmune LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI3617 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01248949 ↗ |
| Modality | Monoclonal antibody | “a human IgG1 kappa monoclonal antibody directed against human angiopoietin-2” PMID 34772758 ↗ Nov 2021 |
| Route | Intravenous | “Participants will receive MEDI3617 via IV infusion” NCT01248949 ↗ |
| Target | ANGPT2 | “a human IgG1 kappa monoclonal antibody directed against human angiopoietin-2” PMID 34772758 ↗ Nov 2021 |